Stock Analysis

3 Growth Companies With Insider Ownership Up To 35%

SHSE:688100
Source: Shutterstock

In the current global market landscape, uncertainty surrounding tariffs and mixed economic signals have led to cautious investor sentiment, with major U.S. indices experiencing slight declines. Despite these challenges, many investors are turning their attention to growth companies where high insider ownership can signal confidence in a company's long-term potential.

Top 10 Growth Companies With High Insider Ownership

NameInsider OwnershipEarnings Growth
Archean Chemical Industries (NSEI:ACI)22.9%50.1%
Seojin SystemLtd (KOSDAQ:A178320)32.1%39.9%
Clinuvel Pharmaceuticals (ASX:CUV)10.4%26.2%
SKS Technologies Group (ASX:SKS)29.7%24.8%
Laopu Gold (SEHK:6181)36.4%38.2%
Pricol (NSEI:PRICOLLTD)25.4%25.2%
Medley (TSE:4480)34.1%27.3%
Plenti Group (ASX:PLT)12.7%120.1%
Fulin Precision (SZSE:300432)13.6%71%
Findi (ASX:FND)35.8%111.4%

Click here to see the full list of 1447 stocks from our Fast Growing Companies With High Insider Ownership screener.

Let's dive into some prime choices out of the screener.

Willfar Information Technology (SHSE:688100)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Willfar Information Technology Co., Ltd. offers smart utility services and IoT solutions both in China and internationally, with a market cap of CN¥18.10 billion.

Operations: Willfar Information Technology Co., Ltd. generates revenue through its smart utility services and IoT solutions across domestic and international markets.

Insider Ownership: 21.2%

Willfar Information Technology is positioned for robust growth, with revenue projected to increase by 21.3% annually, outpacing the broader Chinese market. Despite a price-to-earnings ratio of 30.6x, it remains attractively valued compared to peers and the market average of 36.4x. A recent CNY 150 million share buyback plan underscores management's confidence in future prospects and commitment to shareholder value through equity incentives or employee stock ownership plans.

SHSE:688100 Ownership Breakdown as at Feb 2025
SHSE:688100 Ownership Breakdown as at Feb 2025

Shanghai Aohua Photoelectricity Endoscope (SHSE:688212)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Shanghai Aohua Photoelectricity Endoscope Co., Ltd. operates in the medical equipment industry, focusing on the development and production of endoscopic devices, with a market cap of CN¥5.66 billion.

Operations: The company generates revenue primarily from its diagnostic kits and equipment segment, totaling CN¥750.04 million.

Insider Ownership: 32.3%

Shanghai Aohua Photoelectricity Endoscope is poised for significant growth, with earnings expected to rise by 59.9% annually, surpassing the broader market's pace. Despite a decline in profit margins from 9.8% to 6.7%, the company trades at a discount of 20.8% below its estimated fair value. A CNY 200 million share buyback plan reflects management's confidence, funded partly by a special loan and aimed at equity incentives or employee stock ownership plans.

SHSE:688212 Earnings and Revenue Growth as at Feb 2025
SHSE:688212 Earnings and Revenue Growth as at Feb 2025

Suzhou Sunmun Technology (SZSE:300522)

Simply Wall St Growth Rating: ★★★★★★

Overview: Suzhou Sunmun Technology Co., Ltd. specializes in the research, production, and sale of nano-coloring materials, functional nano-dispersions, special additives, intelligent color matching systems, and electronic chemicals in China with a market cap of approximately CN¥4.61 billion.

Operations: Revenue Segments (in millions of CN¥): Nano-coloring materials: 1,200; Functional nano-dispersions: 950; Special additives: 780; Intelligent color matching systems: 640; Electronic chemicals: 1,150. Suzhou Sunmun Technology generates its revenue from nano-coloring materials (CN¥1.20 billion), functional nano-dispersions (CN¥950 million), special additives (CN¥780 million), intelligent color matching systems (CN¥640 million), and electronic chemicals (CN¥1.15 billion).

Insider Ownership: 35.4%

Suzhou Sunmun Technology is positioned for robust growth, with earnings projected to increase significantly at 92.8% annually, outpacing the CN market's 25.3%. Revenue is also expected to grow rapidly at 48.8% per year, well above the market average of 13.4%. Despite no substantial insider trading activity in recent months, its future return on equity is forecasted to reach a high level of 22.8%, indicating strong potential for value creation.

SZSE:300522 Earnings and Revenue Growth as at Feb 2025
SZSE:300522 Earnings and Revenue Growth as at Feb 2025

Summing It All Up

Ready For A Different Approach?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Valuation is complex, but we're here to simplify it.

Discover if Willfar Information Technology might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About SHSE:688100

Willfar Information Technology

Provides smart utility services and IoT solutions in China and internationally.

High growth potential with solid track record.

Community Narratives

AstraZeneca's Oncology and Obesity Innovations Will Drive Revenue Growth by 10%
Fair Value SEK 2.55k|36.403% undervalued
Unike
Unike
Community Contributor
Leading the Charge in SME SaaS Innovation
Fair Value SEK 100.02|25.014999999999997% undervalued
Investingwilly
Investingwilly
Community Contributor
Brookfield Corporation is a solid BUY for a long-term portfolio
Fair Value CA$82.23|4.1226% overvalued
Jonataninho
Jonataninho
Community Contributor